Last reviewed · How we verify
Recombinant herpes zoster vaccine with high-dose adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Recombinant herpes zoster vaccine with high-dose adjuvant (Recombinant herpes zoster vaccine with high-dose adjuvant) — Shanghai Institute Of Biological Products.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant herpes zoster vaccine with high-dose adjuvant TARGET | Recombinant herpes zoster vaccine with high-dose adjuvant | Shanghai Institute Of Biological Products | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant herpes zoster vaccine with high-dose adjuvant CI watch — RSS
- Recombinant herpes zoster vaccine with high-dose adjuvant CI watch — Atom
- Recombinant herpes zoster vaccine with high-dose adjuvant CI watch — JSON
- Recombinant herpes zoster vaccine with high-dose adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant herpes zoster vaccine with high-dose adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-herpes-zoster-vaccine-with-high-dose-adjuvant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab